CellCarta and Biofidelity today announce an expanded multi-year global strategic partnership, including exclusivity for Aspyre® Lung in clinical trial settings.
"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...
Illumina and Labcorp expand collaboration to advance precision oncology through innovative applications of NGS solutions: San Diego Friday, March 20, 2026, 15:00 Hrs [IST] Illumin ...
All study participants simultaneously underwent NGS using three sample types: (1) BWF, (2) plasma, and (3) tumor tissue collected during bronchoscopy. The full patient set (FPS) included all enrolled ...
The FDA approved the Oncomine Dx Express Test for rapid identification of NSCLC patients eligible for Zegfrovy treatment. The test provides results in 24 hours, aiding timely therapeutic decisions and ...
The Association for Molecular Pathology (AMP), the premier global, non-profit molecular diagnostics professional society, today published consensus recommendations to help clinical laboratory ...
Biodesix recently validated Thermo Fisher’s tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer LOUISVILLE, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Biodesix, ...
Implementing Value-Based Health Care in Surgical Oncology: A Pathway to Improved Outcomes and Efficiency Rare and ultra-rare cancers represent an enormous unmet need that is not addressable with ...
CAMBRIDGE, England and MONTREAL, March 19, 2026 /PRNewswire/ -- CellCarta and Biofidelity today announce an expanded multi-year global strategic partnership, including exclusivity for Aspyre (R) Lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results